Why Alzheimer phase 3 trials fail and how we can improve chances for success: 30 years of clinical drug development
Lon Schneider, MD
Professor of Psychiatry, Neurology, and Gerontology, Keck School of Medicine, University of Southern California
Lon Schneider, MD, MS is Professor of Psychiatry, Neurology, and Gerontology at the Keck School of Medicine of the University of Southern California. He is director of the California Alzheimer’s Disease Center, the Department of Psychiatry Geriatric Studies Center and co-director of the clinical core of the University of Southern California Alzheimer’s Disease Research Center (National Institutes of Health). Dr. Schneider is principal investigator of the National Institute of Mental Health CATIE program, a multicenter effectiveness trial of atypical antipsychotics in Alzheimer’s disease, and he is internationally recognized as an Alzheimer’s disease trialist.